Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mitapivat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Agios Completes Enrollment of Phase 3 RISE UP Study
    Agios Completes Enrollment of Phase 3 RISE UP Study

    23 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/23/2967643/31990/en/Agios-Completes-Enrollment-of-Phase-3-RISE-UP-Study-of-Mitapivat-in-Sickle-Cell-Disease.html

    GLOBENEWSWIRE
    23 Oct 2024
    Share Share
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval
    Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925573/31990/en/Agios-to-Receive-1-1-Billion-in-Milestone-Payments-Following-FDA-Approval-of-Vorasidenib.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results
    Agios Announces Phase 3 ACTIVATE-KidsT Study Results

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2922579/31990/en/Agios-Announces-Results-from-Phase-3-ACTIVATE-KidsT-Study-of-Mitapivat-in-Children-with-PK-Deficiency-Who-Are-Regularly-Transfused.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA
    Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA

    15 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/15/2899255/31990/en/Agios-Presents-Positive-Results-from-Phase-3-ENERGIZE-Study-of-Mitapivat-in-Non-Transfusion-Dependent-Thalassemia-in-Plenary-Session-at-the-European-Hematology-Association-2024-Hyb.html

    GLOBENEWSWIRE
    15 Jun 2024
    Share Share
    Agios' Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias
    Agios' Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892080/31990/en/Agios-Announces-Phase-3-ENERGIZE-T-Study-of-Mitapivat-Met-Primary-Endpoint-and-All-Key-Secondary-Endpoints-in-Adults-with-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
    Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

    03 Jun 2024

    // Mariam Sunny REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/agios-pharmaceuticals-blood-disorder-drug-succeeds-late-stage-study-2024-06-03/

    Mariam Sunny REUTERS
    03 Jun 2024
    Share Share